Chardan Capital analyst Keay Nakae reiterated a Buy rating on Emergent Biosolutions (EBS) today and set a price target of $86.00. The company’s shares closed last Thursday at $73.95.
According to TipRanks.com, Nakae is a 4-star analyst with an average return of 3.2% and a 44.3% success rate. Nakae covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Arcturus Therapeutics, and NeuBase Therapeutics.
Emergent Biosolutions has an analyst consensus of Moderate Buy, with a price target consensus of $71.00.
See today’s analyst top recommended stocks >>
The company has a one-year high of $83.02 and a one-year low of $39.12. Currently, Emergent Biosolutions has an average volume of 531.6K.
Based on the recent corporate insider activity of 61 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of EBS in relation to earlier this year. Most recently, in March 2020, Louis Sullivan, a Director at EBS sold 15,786 shares for a total of $930,585.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It offers specialty products for civilian and military populations that address accidental, intentional and naturally occurring public health threats. The firm’s products include ACAM2000, BioThrax, Raxibacuma, Vaxchora, and VIGIV. Its business units include Vaccines and Anti-Infectives; Antibody Therapeutics; Devices; and Contract Development and Manufacturing. The company was founded by Fuad El-Hibri in May 1998 and is headquartered in Gaithersburg, MD.
